Publikationen
Originalarbeiten (per review)
Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R (2010) Comparison of Intravenous Immunoglobulins for Naturally Occurring Antibodies against b-Amyloid. J Alzheimer’s disease 20(1):135-43.
Bach JP, Kumar N, Depboylu C, Noelker C, Klockgether T, Bacher M, Balzer-Geldsetzer M, Dodel R (2010) Copper deficiency associated with severe neurological disorder – A genetic work-up of possible mutations in copper transport proteins. J Neurol Sci 291(1-2):95-7.
Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R (2010) The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med. 16(3-4):116-21.
Ernst A, Buerger K, Hartmann O, Dodel R, Noelker C, Sommer N, Schwarz M, Köhrle J, Bergmann A, Hampel H (2010) Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. J Neuroimmunol. 221(1-2):62-7.
Decher N, Streit A, Rapedius M, Netter M, Marzian S, Ehling P, Schlichthörl G, Craan T, Renigunta V, Köhler A, Dodel R, Navarro-Pollanco R, Preisig-Müller R, Klebe G, Budde T, Baukrowitz T, Daut J (2010) RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. EMBO J (ahead of print)
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2010) Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. [ahead of print]
Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease (2010) Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord. 2010 May 15;25(7):896-905
Bodden ME, Mollenhauer B, Trenkwalder C, Schimke N, Eggert K, Unger M, Oertel WH, Kessler J, Dodel R, Kalbe E (2010) Affective and cognitive Theory of mind in Patients with Parkinson’s Disease. Parkinsonism and related Disorders (in press)
Reimann J, Schnell S, Schwartz S, Kappes-Horn K, Dodel R Bacher M (2010) Macrophage migration inhibitory factor (MIF) in normal human skeletal muscle and inflammatory myopathies. Journal of Neuropathology and Experimental Neurology (in press)
Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R (2010) Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 257(1):15-23.
Müller-Vahl K, Dodel I, Müller N, Münchau A, Reese JP, Balzer-Geldsetzer M, Dodel R, Oertel WH (2010) Health-related quality of life in patients with Gilles de la Tourette's syndrome. Mov Disord 25(3):309-314.
Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, Oertel WH, Dodel R, Gusev E (2010) Incidence of Parkinson's disease and atypical Parkinsonism: Russian population-based study. Mov Disord 25(3):349-356.
Dodel I, Müller N, Münchau A, Reese JP, Balzer-Geldsetzer M, Dodel R, Oertel WH, Müller-Vahl K (2010) Healthcare utilization in patients with Gilles de la Tourette's syndrome. J Neurol [Epub ahead of print]
Winter Y, Reese JP, Spottke A, Balzer-Geldsetzer M, Baum E, Klotsche J, Rieke J, Simonow A, Eggert K, Oertel WH, Dodel R (2010) Longitudinal Study of the Socioeconomic Burden of Parkinson’s Disease in Germany. Eur J Neurol 2010 (ahead of print)
Reese JP, Campenhausen S, Winter Y, Balzer-Geldsetzer M, Eggert K, Oertel WH, Dodel R (2010) Morbus Parkinson: Krankheitskosten und Versorgungssituation in Deutschland. Gesundheitswesen in press
Dodel R, Happe S, Peglau I, Mayer G, Wasem J, Reese JP, Giani G, Geraedts M, Trenkwalder C, Oertel WH, Stiasny-Kolster K (2010) Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting. Pharmacoeconomics 28(5):381-93.
Rodrigues A, Geldsetzer F, Holdorff B, Kielhorn F, Balzer-Geldsetzer M, Oertel WH, Hurtig H, Dodel R (2010) Who was the man, who discovered the “Lewy Bodies”?. Mov Disord (in press)
Reese JP, Winter Y, Balzer-Geldsetzer M, Bötzel K, Eggert K, Oertel WH, Dodel R, Campenhausen SV (2010) Parkinson's Disease: Cost-of-Illness in an Outpatient Cohort. Gesundheitswesen. 2010 Mar 12. [ahead of print]
Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, Tackenberg B, Mylius V, Reese JP, Kiefer R, Schrank B, Oertel WH, Dodel R (2010) Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. [ahead of print]
Meyer B, Ringel F, Winter Y, Spottke A, Gharevi N, Dams J, Balzer-Geldsetzer M, Müller I, Klockgether T, Schramm J, Urbach H, Dodel R (2010) Health-Related Quality of Life in Patients with Subarachnoid Hemorrhage. Cerebrovascular Dis. (ahead of print)
Winter Y, Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Bötzel K, Eggert K, Oertel WH, Dodel R, Barone P (2010) Costs of Parkinson’s disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study. Neurodegenerative Dis (ahead of print)
Meyer B, Winter Y, Ringel F, Spottke A, Gharevi N, Müller I, Klockgether T, Schramm J, Urbach H, Dodel R (2010) Cost-of-Illness in Subarachnoid Hemorrhage. Stroke (ahead of print)
Siebert U, Bornschein B, Dams J, Eggert K, Herting B, Gasser T, Volkmann J, Bötzel K, Kupsch A, Kraus P, Oertel WH, Wittenberg E, Dodel R (2010) Independent Impact of Dyskinesias on Health-Related Quality of Life in Patients with Parkinson's Disease. J Neurol Neurosur Psy (in press)
Eggert K, Larisch A, Dodel R, Bormann C, Oertel WH (2009) Awareness and Knowledge of the Clinical Practice Guideline on Parkinson’s Disease among German Neurologists. Eur Neurol. 61(4) :216-222
Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R (2009) The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease. Mol Med (ahead of print)
Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese JP, Bacher M (2009) Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer 9(1):464.
Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. (2009) Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25(1):97-107.
Bartnik D, Funke SA, Andrei-Selmer LC, Bacher M, Dodel R, Willbold D (2009) Differently Selected d-Enantiomeric Peptides Act on Different Abeta Species. Rejuvenation Res [ahead of print]
Ehret R, Balzer-Geldsetzer M, Reese JP, Dodel I, Becker E, Christopher A, Friedrich H, Kraemer S, Lüer W, Müngersdorf M, Puzich R, Rohr A, Schultes-Platzek I, Siefjediers V, Tiel-Wilck K, Oertel WH, Dodel R (2009) Direct costs for Parkinson’s treatment in private neurology practices in Berlin. Nervenarzt 80(4): 452-8.
Winter Y, Wolfram C, Schaeg M, Reese JP, Oertel WH, Dodel R, Back T (2009) Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 256(6):954-63.
Schrag A, Spottke A, Quinn NP, Dodel R (2009) Comparative responsiveness of Parkinson’s disease scales to change over time. Mov Disord 24(6):813-8.
Winter Y, Campenhausen S, Popov G, Reese JP, Klotsche J, Boetzel K, Gusev E, Oertel WH, Dodel R, Guekht A (2009) Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease. Pharmacoeconomics 27(7):571-584.
Winter Y, Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, Ruzicka E (2009) Cost of illness of Parkinson’s disease in Eastern Europe: A Czech cohort study. Parkinsonism Relat Disord. 16(1):51-56.
Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Bötzel K, Siebert U, Oertel WH, Dodel R, Poewe W (2009) Cost of illness and health service patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 121(17-18):574-82
Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU (2009) Occurrence Risk and Structure of Depression in Parkinson Disease With and Without Dementia: Results From the GEPAD Study. J Geriatr Psychiatry Neurol 23(1):27-34
Winter Y, von Campenhausen S, Popov G, Reese JP, Balzer-Geldsetzer M, Kukshina A, Zhukova TV, Bertschi N, Bötzel K, Gusev E, Oertel WH, Dodel R, Guekht A (2009) Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. Parkinsonism Relat Disord [ahead of print]
Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Bötzel K, Oertel WH, Dodel R, Poewe W (2009) Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. J Neurol 257(4):638-45.
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson's disease: Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J. Neurol. 255(2):255-64.
Bacher M, Dodel R, Aljabari B, Keyvani K, Marambaud P, Kayed R, Glabe C, Goertz N, Hoppmann A, Sachser N, Klotsche J, Schnell S, Lewejohann L, Al-Abed Y (2008) CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease. J Exp Med. 205(7): 1593-9.
Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel R, Johnstone BH, March KL, Farlow MR, Du Y (2008) IFATS Series: The Conditioned Media of Adipose Stromal Cells Protect Against Hypoxia-Ischemia-Induced Brain Damage in Neonatal Rats. Stem Cells 27(2):478-488.
Bacher M, Depboylu C, Du Y, Noelker C, Staufenbiel M, Behr T, Henriksen G, Behe M, Dodel R (2008) Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid antibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett. 449(3):240-5.
Wei X, Ma Z, Fontanilla CV, Zhao L, Xu ZC, Taggliabraci V, Johnstone BH, Dodel RC, Farlow MR, Du Y (2008) Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity. Neuroscience 155(4):1098-105
Althaus A, Arránz Becker O, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R (2008) Frequency and treatment of depressive symptoms in a Parkinson's disease registry. Parkinsonism Relat Disord 14(8):626-32
Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Ostergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK; on behalf of the European MSA Study Group (EMSA-SG). (2008) Red flags for multiple system atrophy. Mov Disord. 23(8):1093-9.
Popp J, Bacher M, Kölsch H, Noelker C, Deuster O, Dodel R, Jessen F (2008) Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res. 43(8): 749-53.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Lewitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, Lapelle N; for the Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) : Scale presentation and clinimetric testing results. Mov Disord. 23(15) :2129-2170.
Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsch J, Giani G, Geraedts M, Trenkwalder C, Dodel R (2008) Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 10(3):295-305.
Althaus A, Becker OA, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R (2008) Frequency and treatment of depressive symptoms in a Parkinson's disease registry. Parkinsonism Relat Disord 14(8):626-32.
Winter Y, Wolfram C, Schöffski O, Dodel RC, Back T (2008) Long-term disease-related costs 4 years after stroke or TIA in Germany. Nervenarzt 79(8) :918-26.
Wei X, Chen X, Fontanilla C, Zhao L, Liang Z, Dodel R, Hampel H, Farlow M, Du Y (2007) C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line. Life Sci. 80(12):1152-6.
Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord. 22(7):938-45.
Ernst A, Morgenthaler NG, Buerger K, Dodel R, Noelker C, Sommer N, Schwarz M, Koehrle J, Bergmann A, Hampel H (2007) Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. J Neuroimmunol. 189(1-2):169-74.
Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, Dodel R, Otto J, Ebersbach G, Kessler J (2007) Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord. 14(2):93-101.
Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nvenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 22(1):41-7.
Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, Klingmüller D, Dodel R, Wüllner U, Jessen F (2007) CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. Neurobiol Aging 30(3):498-500.
Epifanov Y, Dodel R, Haacke C, Schaeg M, Schöffski O, Hennerici M, Back T (2007) Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. Health Policy 81(2-3):339-49.
Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, Athen O, Köhne-Volland R, Dodel RC (2007) Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. Parkinsonism Relat Disord. 13(2):108-14.
Kalbe E, Riedel O, Kohn N, Dodel R, Calabrese P, Kessler J (2007) Sensitivity and Specificity of the « Parkinson Neuropsychometric Dementia Assessment « (PANDA) : Results of the GEPAD Study. Akt Neurol 34 :140-146.
Dodel R, Peter H, Spottke A, Noelker C, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G (2007) Health-related quality of life in patients with narcolepsy. Sleep Med. 8(7-8):733-41.
Depboylu C, Lohmüller F, Du Y, Riemenschneider M, Kurz A, Gasser T, Müller U, Dodel RC (2006) Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci Lett. 400(3):187-90.
Ma Z, Wei X, Fontanilla C, Noelker C, Dodel R, Hampel H, Du Y (2006) Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. Life Sci. 79(13):1307-11.
Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R (2006) Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 37(1):193-8.
Riedel O, Dodel R, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel WH, Reichmann H, Riederer P, Trenkwalder C, Wittchen HU (2006) Physician-Related Prevalence of Dementia, Depressive and Psychotic Symptoms in Patients with Parkinson’s Disease. Akt Neurologie 33:274-380.
Hamer HM, Spottke A, Aletsee C, Knake S, Reis J, Strzelczyk A, Oertel WH, Rosenow F, Dodel R (2006) Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 47(12):2165-72.
Wei X, Zhao L, Liu J, Dodel RC, Farlow MR, Du Y (2005) Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation. Neuroscience 131(2):513-21.
Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, Dodel R, Du Y, Moller HJ, Bergmann A, Hampel H (2005) Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 57(7):813-6.
Noelker C, Bacher M, Gocke P, Wei X, Klockgether T, Du Y, Dodel R (2005) The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity. Neurosci Lett 383(1-2):39-43.
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. (2005) Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics: 817-36.
Moller JC, Korner Y, Dodel RC, Meindorfner C, Stiasny-Kolster K, Spottke A, Kruger HP, Oertel WH (2005) Pharmacotherapy of Parkinson's disease in Germany. J Neurol 252(8):926-35.
Übersichtsarbeiten
Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70(5):513-28.
Dodel R, Bacher M (2009) Innovative treatment approaches for Alzheimer's disease. Immunotherapy. Nervenarzt 79 Suppl 3:149-57; quiz 158.
Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M (2009) The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115(10):2031-40.
Röskam S, Neff F, Schwarting R, Bacher M, Dodel R (2009) APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 34(4):487-99.
Bodden ME, Dodel R, Kalbe E (2009) Theory of mind in Parkinson’s disease and related basal ganglia disorders: A systematic review. Mov Disord 25(1):13-27.
Reese JP, Balzer M, Dodel R (2009) Alzheimer-Erkrankung: gesundheits-ökonomische Aspekte. Neuro aktuell 178:20-22
Dodel R, Bodden M (2009) State of the Art – Alzheimer-Demenz. PharmaFokus ZNS 6. Jahrgang Sep 2009: 44-50.
Antonini A, Dodel R, Odin P, Lorrain M, Volkmann J, Reichmann H, Storch A, Poewe W (2009) Im Fokus: L-Dopa-Pumpe, Apomorphin-Pumpe, Tiefe Hirnstimulation. Therapiemöglichkeiten beim fortgeschrittenen Morbus Parkinson. Thieme Drug Report 4:1-11.
Schepelmann K, Dodel R (2009) Krankheitskosten in Deutschland – Neuromuskuläre Erkrankungen. Neuro aktuell 6/09 Nr. 183
Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, Oechsner M, Jost W, Reichmann H, Schulz JB (2008) Lewy body dementia and Parkinson’s disease with dementia. J Neurol 255(5):34-43.
Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 7(6):501-7.
Schneider F, Althaus A, Backes V, Dodel R (2008) Psychiatric Symptoms in Parkinson’s Disease. European Archives of Psychiatry and Clinical Neuroscience 258 Suppl 5:55-9.
Schmidt R, Neff F, Lampl C, Benke T, Anditsch M, Bancher C, Dal-Bianco P, Reisecker F, Marksteiner J, Rainer M, Kapeller P, Dodel R (2008) Therapie of Alzheimer’s Disease: Current status and future development. Neuropsychiatr. 22(3):153-71
Bach JP, Rinn B, Meyer B, Dodel R, Bacher M (2008) Role of MIF in inflammation and tumorigenesis. Oncology 75(3-4):127-33
Strzelczyk A, Reese JP, Dodel R, Hamer HM (2008) Cost of Epilepsy : A systematic Review. PharmacoEconomics. 26(6) : 463-476
Strzelczyk A, Nickolay T, Reese JP, Bauer S, Knake S, Rosenow F, Dodel R, Hamer HM (2008) Die direkten und indirekten Kosten therapierefraktärer Epilepsie. Neuro Rehabil 14(3) :133-140.
Winter Y, Dodel R, Haacke C, Schaeg M, Schöffski O, Oertel W, Bach T (2008) Kostenstruktur der Schlaganfallsbehandlung in Deutschl. Neuro & Rehabil 14(2) :59-65.
Eggert K, Reese JP, Oertel WH, Dodel R (2008) Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease. CNS Drugs 22(10) :841-60.
Dodel R, Bach JP, Oertel WH (2008) Geist und Seele in Mitleidenschaft. Ärztliche Praxis Neurologie und Psychiatrie 6/2008 : 39-45.
Dodel R, Reese, JP, Balzer M (2008) The Economic Burden of Parkinson’s Disease. European Neurological Review Vol. 3 Issue 2 Supplement : III Int. Forum on Advanced Parkinson’s Disease : 11-14.
Wentrup A, Oertel WH, Dodel R (2008) Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease. Drug Design, Development and Therapie 2 245–254.
Brand S, Dodel R, Hautzinger M, Gründer G, Althaus A, Schneider F (2007) Depression in Parkinson's disease. Assessment and treatment. Nervenarzt. 78(6):715-27.
Walbert T, Reese JP, Dodel R (2007) Krankheitskosten neurologischer Erkrankungen in Deutschland. Cost-of-illness in neurological diseases in Germany. Nervenheilkunde 26(4): 260-268.
Althaus A, Kanis T, Spottke A, Eggert K, Liepelt I, Berg D, Schneider F, Dodel R (2007) Benchmarking in der Patientenversorgung. Benchmarking in patient’s care. Nervenheilkunde 26(4): 277-280
Dodel R, Spottke A (2007) Ökonomische Analyse des Parkinson-Syndroms – Kompetenznetz Parkinson. Economic analysis of the Parkinson sydrome – Competence Network Parkinson. Nervenheilkunde 26(4): 256-259.
Dodel R, Rosenow F, Hamer HM (2007) The costs of epilepsy in Germany. Pharm Unserer Zeit. 36(4):298-305.
Eggert K, Dodel R, Franke S, Oertel WH (2007) Leitlinien für Diagnose und Therapie der Parkinson-Syndrome. Guidelines for diagnosis and therapy of parkinsonian syndromes. Nervenheilkunde 26(4): 269-276.
Eggert K, Baas H, Deuschl G, Dodel R, Franke S, GasserT, Klockgether T, Reichmann H, Trenkwalder C, Wüllner U, Oertel WH (2007) Das Kompetenznetz Parkinson. Nervenheilkunde 2007 26 (4): 239-240.
Reese JP, Stiasny-Kolster K, Oertel WH, Dodel RC (2007) Health-related quality of life and economic burden in patients with restless legs syndrome. Expert Rev Pharmacoeconmics Outcomes Res. 7(5):503-21.
Müller T, Dodel R, Fritze J (2006) Cost and quality aspects in the treatment of Parkinson's disease. Z Arztl Fortbild Qualitatssich. 100(4):291-5.
von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 15(4):473-90.
Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, Del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK (2005) The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm. 112(12):1677-86.
Schulz JB, Benecke R, Dodel R, Eggert K, Fogel W, Gerlach M, Reichmann H, Riederer P, Schwartz A, Winkler J (2005) Stepwise Diagnostics for Parkinsonian Syndromes. Akt Neurologie 32:97-101.
Lindgren P. von Campenhausen S, Spottke E, Siebert U, Dodel R (2005). Cost of Parkinson's disease in Europe. Eur J Neurol 12 Suppl 1:68-73.
Buchkapitel und Herausgeberschaften
Dodel RC, Klockgether T (2010) Kurzlehrbuch der Neurologie für Studenten. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
Balzer-Geldsetzer M, Amelung G, Dodel R, Meier B. Innovative Konzepte im Versorgungsmanagement von ZNS-Patienten. Hrsg. Amelung, Bergmann, Falkai, Hauth, Jaleel, Meier, Reichmann, Roth-Sackenheim. Kapitel 3: Versorgungssituation von Patienten mit neurologischen Erkrankungen in Deutschland. Medizinisch Wissenschaftliche Verlagsgesellschaft.
Dodel R, Schrag A (2009) V.R. Preedy, R.R. Watson (Hrsg) Health-related Quality of Life in Movement Disorders. Handbook of Disease Burdens and Quality of Life Measures, Springer Verlag.
Agbo DB, Neff F, Seitz F, Binder C, Oertel WH, Bacher M, Dodel R (2009) Immunization as Treatment for Parkinson’s Disease. In: Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. G. DiGiovanni, V. DiMatteo, E. Esposito (Hrsg). Springer-Verlag. 311-315
Dodel R, Schneider F, Spieker S (2008) Depression. Capital 2.2.2: 31-36. The Treatment of Advanced Parkinson’s Disease/Jost W. UNI-MED Science Verlag.
Dodel R (2008) Dementia. Capital 2.2.3: 32-37. The Treatment of Advanced Parkinson’s Disease/Jost W. UNI-MED Science Verlag.
Dodel R, Siebert U, Wasem J (2008) Kapitel: Gesundheitsökonomische Bewertungen. Neuro-Psychopharmaka Band 1 Springer Verlag.
Handbook of Disease Burdens and Quality of Life Measures. Kapitel: Health-related Quality of Life in Movement Disorders (2008) Springer Verlag.
Dodel R, Siebert U, Wasem J (2008) Grundlagen der Neuro-Psychopharmakologie. Hrsg. Riederer, Laux. Kapitel: Gesundheits-ökonomische Bewertungen, Springer Verlag.
Dodel R, Schneider F, Spieker S (2007) Depression. Kapitel 2.2.2: 31-36. Therapie des fortgeschrittenen Parkinson-Syndroms/Jost W. UNI-MED Verlag.
Enzyklopädie der Schlafmedizin, Hrsg: Peter H, Penzel T, Hermann J, Kapitel Pharmakökonomie 910-913 (2007) Springer Verlag.
Dodel R (2007) Demenz. Kapitel 2.2.3: 37-41. Therapie des fortgeschrittenen Parkinson-Syndroms/Jost W. UNI-MED Verlag.
The Status of health in the European Union: Towards a healthier Europe. Report im Rahmen des Eugloreh-Projektes 2007
Eggert KM, Deuschl G, Gasser T, Oertel WH, Arnold G, Baas H, Dodel R, Mehdorn HM, Przuntek W, Reichmann H, Riederer P, Spieker S, Trenkwalder C (2005) Leitlinie Parkinson-Syndrome. Georg Thieme Verlag
fallberichte
Bach JP, Oertel WH, Dodel R, Jessen F (2009) Treatment of hypersexuality in Parkinson’s disease with carbamazepine – A case report. Mov Disord 24(8):1241-2.
Bach JP, Sommer N, Möller JC, Oertel WH, Dodel R, Gasser T (2008) Parkinson's syndrome in a young patient with Klinefelter's syndrome -A case report. Mov Disord 23(5):771-2.
Freymann M, Dodel R, Jessen F (2005) Successful treatment of sexual disinhibition with carbamazepine in patients with dementia. Pharmacopsychiatry 38(3):144-5.
Clemen C, Spottke A, Lüttjohann K, Urbach H, Klockgether T, Dodel R (2005) Cerebrotendinous Xanthomathosis. Neurology 64(8):1476.